drugset / Trial / NCT05367635

A Study of SKB315 in Patients With Advanced Solid Tumors

NCT05367635

Phase 1 Recruiting 246 enrolled Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a multicenter, open-label, multiple-dose dose finding and expansion study to evaluate the safety, tolerability, pharmacokinetic(PK) profile, and anti-tumor efficacy of SKB315 for injection in patients with advanced solid tumors.

Timeline

Start
2022-03-16
Primary completion
2026-06-30
Completion
2028-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject SKB315 Unknown
Background Capecitabine Small molecule
Background KL-A167 Unknown

Indications